Curcumin Cancer Research Results

CUR, Curcumin: Click to Expand ⟱
Features:
Curcumin is the main active ingredient in Tumeric. Member of the ginger family.Curcumin is a polyphenol extracted from turmeric with anti-inflammatory and antioxidant properties.
- Has iron-chelating, iron-chelating properties. Ferritin. But still known to increase Iron in Cancer cells.
- GSH depletion in cancer cells, exhaustion of the antioxidant defense system. But still raises GSH↑ in normal cells.
- Higher concentrations (5-10 μM) of curcumin induce autophagy and ROS production
- Inhibition of TrxR, shifting the enzyme from an antioxidant to a prooxidant
- Strong inhibitor of Glo-I, , causes depletion of cellular ATP and GSH
- Curcumin has been found to act as an activator of Nrf2, (maybe bad in cancer cells?), hence could be combined with Nrf2 knockdown
-may suppress CSC: suppresses self-renewal and pathways (Wnt/Notch/Hedgehog).
Clinical studies testing curcumin in cancer patients have used a range of dosages, often between 500 mg and 8 g per day; however, many studies note that doses on the lower end may not achieve sufficient plasma concentrations for a therapeutic anticancer effect in humans.
• Formulations designed to improve curcumin absorption (like curcumin combined with piperine, nanoparticle formulations, or liposomal curcumin) are often employed in clinical trials to enhance its bioavailability.

-Note half-life 6 hrs.
BioAv is poor, use piperine or other enhancers
Pathways:
- induce ROS production at high concentration. Lowers ROS at lower concentrations
curcumin can act as a pro-oxidant when blue light is applied
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓
- Lowers AntiOxidant defense in Cancer Cells: GSH↓ Catalase↓ HO1↓ GPx↓
but conversely is known as a NRF2↑ activator in cancer
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, uPA↓, VEGF↓, NF-κB↓, CXCR4↓, SDF1↓, TGF-β↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMT1↓, DNMT3A↓, EZH2↓, P53↑, HSP↓, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, ERK↓, EMT↓, TOP1↓, TET1↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, HK2↓, ECAR↓, OXPHOS↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, CK2↓, Hh↓, GLi1↓, CD133↓, CD24↓, β-catenin↓, n-myc↓, sox2↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK↓, ERK↓, JNK, TrxR**,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 NF-κB signaling ↓ NF-κB activation ↓ inflammatory NF-κB tone Driver Suppression of survival and inflammatory transcription NF-κB is a primary, repeatedly validated curcumin target explaining pleiotropic downstream effects
2 STAT3 signaling ↓ STAT3 phosphorylation / activity ↔ or mild suppression Driver Loss of pro-survival and proliferative signaling STAT3 inhibition contributes to growth arrest, apoptosis sensitization, and reduced cytokine signaling in tumors
3 Reactive oxygen species (ROS) ↑ ROS (dose- & context-dependent) ↓ ROS / buffered Conditional Driver Biphasic redox modulation Curcumin can act as a pro-oxidant in cancer cells with high basal stress while acting antioxidant in normal cells
4 Mitochondrial integrity / intrinsic apoptosis ↓ ΔΨm; ↑ caspase activation ↔ preserved Driver Execution of intrinsic apoptosis Mitochondrial dysfunction and caspase activation occur downstream of NF-κB/STAT3 and ROS effects
5 PI3K → AKT → mTOR axis ↓ AKT / ↓ mTOR ↔ or adaptive suppression Secondary Reduced growth and anabolic signaling AKT/mTOR inhibition contributes to growth suppression and autophagy induction in cancer cells
6 Autophagy ↑ autophagy (protective or pro-death) ↑ adaptive autophagy Secondary Stress adaptation vs cell death Autophagy may be cytoprotective or cooperate with apoptosis depending on context and dose
7 HIF-1α / VEGF hypoxia–angiogenesis axis ↓ HIF-1α; ↓ VEGF ↔ minimal effect Secondary Anti-angiogenic pressure Suppression of hypoxia-driven transcription limits angiogenesis and tumor adaptation
8 Cell cycle regulation ↑ G2/M or G1 arrest ↔ largely spared Phenotypic Cytostatic growth control Cell-cycle arrest reflects upstream signaling and epigenetic effects rather than direct CDK inhibition
9 Migration / invasion (EMT, MMP axis) ↓ migration & invasion ↔ Phenotypic Anti-metastatic phenotype Reduced EMT markers and protease activity limit invasive behavior
10 Epigenetic regulation (p300/CBP HAT activity) ↓ histone acetylation ↔ modest Secondary Transcriptional reprogramming Curcumin modulates chromatin via HAT inhibition rather than classic HDAC inhibition


Scientific Papers found: Click to Expand⟱
2979- CUR,  GB,    Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
- in-vitro, Lung, H157 - in-vitro, Lung, H1299
EGFR↓, Sp1/3/4↓, ERK↓, MEK↓, Akt↓, S6K↓,
2978- CUR,    N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells
- in-vitro, Lung, A549
ROS↑, hTERT/TERT↓, Sp1/3/4↓, eff↓,
2977- CUR,    Curcumin Down-Regulates Toll-Like Receptor-2 Gene Expression and Function in Human Cystic Fibrosis Bronchial Epithelial Cells
- in-vitro, CF, NA
*TLR2↓, *Sp1/3/4↓,
2976- CUR,    Curcumin suppresses the proliferation of oral squamous cell carcinoma through a specificity protein 1/nuclear factor‑κB‑dependent pathway
- in-vitro, Oral, HSC3 - in-vitro, HNSCC, CAL33
tumCV↓, Sp1/3/4↓, p65↓, HSF1↓, NF-kB↓,
2975- CUR,    Curcumin inhibits proliferation, migration and neointimal formation of vascular smooth muscle via activating miR-22
- in-vivo, Nor, NA
*miR-22↑, *Sp1/3/4↓,
455- CUR,    Curcumin Affects Gastric Cancer Cell Migration, Invasion and Cytoskeletal Remodeling Through Gli1-β-Catenin
- in-vitro, GC, SGC-7901
Shh↓, Gli1↓, FOXM1↓, β-catenin/ZEB1↓, TumCMig↓, Apoptosis↑, TumCCA↑, Wnt↓, EMT↓, E-cadherin↑, Vim↓,
472- CUR,    Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis
- vitro+vivo, Ovarian, SKOV3 - vitro+vivo, Ovarian, A2780S
TumCP↓, Apoptosis↑, PCNA↓, miR-320a↓, BAX↑, cl‑Casp3↑, circ‑PLEKHM3↑, SMG1↑,
456- CUR,    Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells
- vitro+vivo, GC, SGC-7901
miR-34a↑, TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, Bcl-2↓, CDK4/6↓, cycD1/CCND1↓,
457- CUR,    Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling
- in-vitro, GC, SGC-7901 - in-vitro, GC, BGC-823
TumCP↓, Apoptosis↑, TumAuto↑, P53↑, PI3K↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, Bcl-xL↓, LC3I↓, BAX↑, Beclin-1↑, cl‑Casp3↑, cl‑PARP↑, LC3II↑, ATG3↑, ATG5↑,
458- CUR,    Curcumin suppresses gastric cancer by inhibiting gastrin‐mediated acid secretion
- vitro+vivo, GC, SGC-7901
Casp3↑, Apoptosis↑, TumCP↓,
459- CUR,    Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells
- in-vitro, Bladder, T24/HTB-9 - in-vitro, Bladder, RT4
Trop2↓, Apoptosis↑, cycE1↓, p27↑, TumCCA↑,
460- CUR,    Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer
- in-vitro, Bladder, T24/HTB-9 - in-vitro, Bladder, TCCSUP - in-vitro, Bladder, J82
miR-7641↓, p16↑, Apoptosis↑, TumCI↓,
461- CUR,    Curcumin inhibits prostate cancer progression by regulating the miR-30a-5p/PCLAF axis
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, miR-30a-5p↑, PCLAF↓, Bcl-2↓, Casp3↓, BAX↑, cl‑Casp3↑,
462- CUR,    Curcumin promotes cancer-associated fibroblasts apoptosis via ROS-mediated endoplasmic reticulum stress
- in-vitro, Pca, PC3
Bcl-2↓, MMP↓, cl‑Casp3↑, BAX↑, BIM↑, p‑PARP↑, PUMA↑, p‑P53↑, ROS↑, p‑ERK↑, p‑eIF2α↑, CHOP↑, ATF4↑,
463- CUR,    Curcumin induces autophagic cell death in human thyroid cancer cells
- in-vitro, Thyroid, K1 - in-vitro, Thyroid, FTC-133 - in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, 8505C
TumAuto↑, LC3II↑, Beclin-1↑, p‑p38↑, p‑JNK↑, p‑ERK↑, p62↓, p‑PDK1↓, p‑Akt↓, p‑p70S6↓, p‑PIK3R1↓, p‑S6↓, p‑4E-BP1↓,
464- CUR,    Curcumin inhibits the viability, migration and invasion of papillary thyroid cancer cells by regulating the miR-301a-3p/STAT3 axis
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, TPC-1
TumCI↓, TumCI↓, MMP2↓, MMP9↓, EMT↓, STAT3↓, miR-301a-3p↓, STAT↓, N-cadherin↓, Vim↓, Fibronectin↓, p‑JAK↓, p‑JAK2↓, p‑JAK3↓, p‑STAT1↓, p‑STAT2↓, E-cadherin↑,
465- CUR,    Curcumin inhibits the growth of liver cancer by impairing myeloid-derived suppressor cells in murine tumor tissues
- vitro+vivo, Liver, HepG2 - vitro+vivo, Liver, HUH7 - vitro+vivo, Liver, MHCC-97H
TumCG↓, MDSCs↓, TLR4↓, NF-kB↓, IL6↓, IL1↓, PGE2↓, COX2↓, GM-CSF↓, angioG↓, VEGF↓, CD31↓, GM-CSF↓, α-SMA↓, p‑IKKα↓, MyD88↓,
466- CUR,    Curcumin circumvent lactate-induced chemoresistance in hepatic cancer cells through modulation of hydroxycarboxylic acid receptor-1
- in-vitro, Liver, HepG2 - in-vitro, Liver, HuT78
GlucoseCon↓, lactateProd↓, pH↑, NO↑, LAR↓, Hif1a↓, LDHA↓, MCT1↓, MDR1↓, STAT3↓, HCAR1↓,
467- CUR,    Curcumin inhibits liver cancer by inhibiting DAMP molecule HSP70 and TLR4 signaling
- in-vitro, Liver, HepG2
TumCP↓, TumCI↓, TumMeta↓, Apoptosis↑, HSP70/HSPA5↓, e-HSP70/HSPA5↓, TLR4↓,
468- CUR,  5-FU,    Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5-fluorouracil in vivo by increasing curcumin bioavailability
- vitro+vivo, Liver, HepG2 - vitro+vivo, Liver, 402 - vitro+vivo, Liver, Bel7
Apoptosis↑, TumCCA↑, PI3k/Akt/mTOR↓, p‑PI3K↓, Bacteria↑, cl‑Casp3↑,
469- CUR,    The inhibitory effect of curcumin via fascin suppression through JAK/STAT3 pathway on metastasis and recurrence of ovary cancer cells
- in-vitro, Ovarian, SKOV3
fascin↓, STAT3↓, JAK↓,
470- CUR,    Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line
- in-vitro, Ovarian, SKOV3
Wnt/(β-catenin)↓, EMT↓, DNMT3A↓, cycD1/CCND1↓, cMyc↓, Fibronectin↓, Vim↓, E-cadherin↑, SFRP5↑,
471- CUR,    Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S
Apoptosis↑, TumAuto↑, p62↓, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, Casp9↑, PARP↑, ATG3↑, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↑,
433- CUR,    Curcumin Inhibits the Migration and Invasion of Non-Small-Cell Lung Cancer Cells Through Radiation-Induced Suppression of Epithelial-Mesenchymal Transition and Soluble E-Cadherin Expression
- in-vitro, Lung, A549
E-cadherin↓, Vim↓, Slug↓, N-cadherin↓, Snail↓, MMP9↓, EMT↓,
443- CUR,    Reduced Caudal Type Homeobox 2 (CDX2) Promoter Methylation Is Associated with Curcumin’s Suppressive Effects on Epithelial-Mesenchymal Transition in Colorectal Cancer Cells
- in-vitro, CRC, SW480
DNMT1↓, DNMT3A↓, N-cadherin↓, Vim↓, Wnt↓, Snail↓, Twist↓, β-catenin/ZEB1↓, E-cadherin↑, EMT↓, CDX2↓,
437- CUR,    Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids
- vitro+vivo, CRC, TCO1 - vitro+vivo, CRC, TCO2
cycD1/CCND1↓, cMyc↓, p‑ERK↓, CD44↓, CD133↓, LGR5↓, TumCCA↑, TumVol↓, CSCs↓,
434- CUR,    Curcumin induces apoptosis in lung cancer cells by 14-3-3 protein-mediated activation of Bad
- in-vitro, Lung, A549
14-3-3 proteins↓, p‑BAD↓, p‑Akt↓, Akt↓, cl‑Casp9↑, cl‑PARP↑,
435- CUR,    Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway
- in-vitro, Lung, A549
Apoptosis↑, TumAuto↑, LC3‑Ⅱ/LC3‑Ⅰ↑, Beclin-1↑, p62↓, PI3K↓, Akt↓, mTOR↓, p‑Akt↓, p‑mTOR↓,
436- CUR,    Integrated microRNA and gene expression profiling reveals the crucial miRNAs in curcumin anti‐lung cancer cell invasion
- in-vitro, Lung, A549
miR-25-5p↓, miR-330-5p↑, MAPK↓, Wnt↓,
9- CUR,    Curcumin Suppresses Malignant Glioma Cells Growth and Induces Apoptosis by Inhibition of SHH/GLI1 Signaling Pathway in Vitro and Vivo
- vitro+vivo, MG, U87MG - vitro+vivo, MG, T98G
HH↓, Shh↓, Gli1↓, cycD1/CCND1↓, Bcl-2↓, FOXM1↓, Bax:Bcl2↑, TumCP↓, TumCMig↓, Apoptosis↑, TumVol↑, TumCCA↑, Casp3↑, OS↑,
438- CUR,    Curcumin Reduces Colorectal Cancer Cell Proliferation and Migration and Slows In Vivo Growth of Liver Metastases in Rats
- vitro+vivo, CRC, CC531
TumCP↓, TumVol↓, Albumin↑, ALP↑, AST↑, ALAT↑, cholinesterase↓,
439- CUR,    Curcumin suppresses LGR5(+) colorectal cancer stem cells by inducing autophagy and via repressing TFAP2A-mediated ECM pathway
- in-vitro, CRC, LGR5
Apoptosis↑, TumAuto↑, GP1BB↓, COL9A3↓, COMP↓, AGRN↓, ITGB4↓, LAMA5↓, COL2A1↓, ITGB6↓, LGR5↓, TFAP2A↓, ECM/TCF↓,
440- CUR,    Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells
- vitro+vivo, CRC, SW480 - vitro+vivo, CRC, HT-29
NNMT↓, p‑STAT3↓, TumCP↓, TumCCA↑, ROS↑,
441- CUR,    Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells through Its Effects on miR-409-3p
- in-vitro, CRC, HCT116
ERCC1↓, Bcl-2↓, GSTP1/GSTπ↓, MRP↓, P-gp↓, miR-409-3p↑, survivin↓,
442- CUR,  5-FU,    Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress
- in-vitro, CRC, HCT116
Apoptosis↑, TumCP↓, TumCCA↑, TET1↑, NKD2↑, Wnt↓, EMT↓, Vim↑, E-cadherin↓, β-catenin/ZEB1↓, TCF↓, AXIN1↓,
454- CUR,    Curcumin-Induced DNA Demethylation in Human Gastric Cancer Cells Is Mediated by the DNA-Damage Response Pathway
- in-vitro, GC, MGC803
TumCMig↓, TumCP↓, ROS↑, mtDam↑, DNAdam↑, Apoptosis↑, ATR↑, P21↑, p‑P53↑, GADD45A↑, p‑γH2AX↑,
444- CUR,  Cisplatin,    LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells
- vitro+vivo, CRC, HCT8
TumVol↓, Apoptosis↑, Bcl-2↓, Cyt‑c↑, BAX↑, cl‑Casp3↑, cl‑PARP1↑, miR-497↑, KCNQ1OT1↓,
445- CUR,    Curcumin Regulates the Progression of Colorectal Cancer via LncRNA NBR2/AMPK Pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, HCT8 - in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
p‑AMPK↑, p‑ACC-α↑, NBR2↑, p‑S6K↓, mTOR↓,
446- CUR,    The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A Possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemoresistant Colorectal Cancer Cells
- in-vitro, CRC, SW480
IR↓, IGF-1↓, Myc↓, TumCMig↓, TumCP↓,
447- CUR,  OXA,    Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway
- vitro+vivo, CRC, HCT116
p‑p65↓, Bcl-2↓, Casp3↑, EMT↓, p‑SMAD2↓, p‑SMAD3↓, N-cadherin↓, TGF-β↓, E-cadherin↑, TumVol↓, TumCMig↓,
448- CUR,    Heat shock protein 27 influences the anti-cancer effect of curcumin in colon cancer cells through ROS production and autophagy activation
- in-vitro, CRC, HT-29
Apoptosis↑, TumCCA↑, p‑Akt↓, Akt↓, Bcl-2↓, p‑BAD↓, BAD↑, cl‑PARP↑, ROS↑, HSP27↑, Beclin-1↑, p62↑, GPx1↓, GPx4↓,
449- CUR,    Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-Catenin Pathways via miR-130a
- vitro+vivo, CRC, SW480
TumCP↓, β-catenin/ZEB1↓, TCF↓, miR-21↓, NKD2↑, miR-130a↓,
450- CUR,    Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44
- in-vitro, CRC, HCT116 - in-vitro, CRC, HCT8
TumCP↓, TumCMig↓, CD44↓, CSCs↓,
451- CUR,    The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer
- vitro+vivo, HNSCC, SCC15 - vitro+vivo, HNSCC, SNU1076 - vitro+vivo, HNSCC, SNU1041
TumCMig↓, TumCG↓, PD-L1↓, PD-L2↓, Galectin-9↓, EMT↓, T-Cell↑, TILs↑, PD-1↓, TIM-3↓, CD4+↓, CD25+↓, FoxP3+↓, E-cadherin↑, CD8+↑, IFN-γ↑,
452- CUR,    Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells
- vitro+vivo, HNSCC, SCC9 - vitro+vivo, HNSCC, FaDu - vitro+vivo, HNSCC, HaCaT
TumCCA↑, PI3k/Akt/mTOR↓, Casp3↑, EGFR↓, EGF↑, PRKCG↑, p‑Akt↓, p‑mTOR↓, RPS6KA1↓, EIF4E↓, proCasp3↓,
453- CUR,    Cellular uptake and apoptotic properties of gemini curcumin in gastric cancer cells
- in-vitro, GC, AGS
Bcl-2↓, survivin↓, BAX↑, TumCCA↑,
1609- CUR,  EA,    Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells
- in-vitro, Cerv, NA
eff↑, Dose∅, ROS↑, DNAdam↑, P53↑, P21↑, BAX↑, Dose∅,
1409- CUR,    Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma
- in-vivo, CCA, Walker256
TumCG↓, ROS↑, MMP↓, STAT3↓, TumCCA↑, eff↓,
1410- CUR,    Curcumin induces ferroptosis and apoptosis in osteosarcoma cells by regulating Nrf2/GPX4 signaling pathway
- vitro+vivo, OS, MG63
tumCV↓, Apoptosis↑, TumCG↓, NRF2↓, GPx4↓, HO-1↓, xCT↓, ROS↑, MDA↑, GSH↓,
1411- CUR,  Cisplatin,    Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects
- Review, Var, NA
ChemoSen↑, *ROS↓, *NF-kB↓, TumCCA↑,

Showing Research Papers: 101 to 150 of 293
Prev Page 3 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 293

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GPx1↓, 1,   GPx4↓, 2,   GSH↓, 1,   GSTP1/GSTπ↓, 1,   HO-1↓, 1,   MDA↑, 1,   NRF2↓, 1,   ROS↑, 8,   xCT↓, 1,  

Mitochondria & Bioenergetics ⓘ

EGF↑, 1,   MEK↓, 1,   MMP↓, 2,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

p‑ACC-α↑, 1,   ALAT↑, 1,   p‑AMPK↑, 1,   cMyc↓, 2,   ERCC1↓, 1,   GlucoseCon↓, 1,   IR↓, 1,   lactateProd↓, 1,   LAR↓, 1,   LDHA↓, 1,   NNMT↓, 1,   p‑PDK1↓, 1,   PI3k/Akt/mTOR↓, 2,   p‑PIK3R1↓, 1,   p‑S6↓, 1,   S6K↓, 1,   p‑S6K↓, 1,  

Cell Death ⓘ

14-3-3 proteins↓, 1,   Akt↓, 4,   p‑Akt↓, 7,   Apoptosis↑, 18,   BAD↑, 1,   p‑BAD↓, 2,   BAX↑, 7,   Bax:Bcl2↑, 1,   Bcl-2↓, 10,   Bcl-xL↓, 1,   BIM↑, 1,   Casp3↓, 1,   Casp3↑, 4,   cl‑Casp3↑, 6,   proCasp3↓, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 1,   hTERT/TERT↓, 1,   p‑JNK↑, 1,   MAPK↓, 1,   MCT1↓, 1,   miR-497↑, 1,   miR-7641↓, 1,   Myc↓, 1,   p27↑, 1,   p‑p38↑, 1,   PUMA↑, 1,   survivin↓, 2,  

Kinase & Signal Transduction ⓘ

miR-25-5p↓, 1,   p‑p70S6↓, 1,   Sp1/3/4↓, 3,  

Transcription & Epigenetics ⓘ

COMP↓, 1,   KCNQ1OT1↓, 1,   miR-21↓, 1,   miR-30a-5p↑, 1,   miR-409-3p↑, 1,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   p‑eIF2α↑, 1,   HSF1↓, 1,   HSP27↑, 1,   HSP70/HSPA5↓, 1,   e-HSP70/HSPA5↓, 1,  

Autophagy & Lysosomes ⓘ

ATG3↑, 2,   ATG5↑, 1,   Beclin-1↑, 5,   LC3‑Ⅱ/LC3‑Ⅰ↑, 2,   LC3I↓, 1,   LC3II↑, 2,   p62↓, 3,   p62↑, 1,   TumAuto↑, 5,  

DNA Damage & Repair ⓘ

ATR↑, 1,   DNAdam↑, 2,   DNMT1↓, 1,   DNMT3A↓, 2,   GADD45A↑, 1,   NBR2↑, 1,   p16↑, 1,   P53↑, 2,   p‑P53↑, 2,   PARP↑, 1,   p‑PARP↑, 1,   cl‑PARP↑, 3,   cl‑PARP1↑, 1,   PCLAF↓, 1,   PCNA↓, 1,   SMG1↑, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 4,   cycE1↓, 1,   P21↑, 3,   TFAP2A↓, 1,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State ⓘ

p‑4E-BP1↓, 1,   AXIN1↓, 1,   CD133↓, 1,   CD44↓, 2,   CDX2↓, 1,   CSCs↓, 2,   EIF4E↓, 1,   EMT↓, 8,   ERK↓, 1,   p‑ERK↓, 1,   p‑ERK↑, 2,   FOXM1↓, 2,   Gli1↓, 2,   HH↓, 1,   IGF-1↓, 1,   LGR5↓, 2,   miR-330-5p↑, 1,   miR-34a↑, 1,   mTOR↓, 2,   p‑mTOR↓, 4,   NKD2↑, 2,   p‑P70S6K↓, 1,   PI3K↓, 2,   p‑PI3K↓, 1,   circ‑PLEKHM3↑, 1,   PRKCG↑, 1,   RPS6KA1↓, 1,   SFRP5↑, 1,   Shh↓, 2,   STAT↓, 1,   p‑STAT1↓, 1,   p‑STAT2↓, 1,   STAT3↓, 4,   p‑STAT3↓, 1,   TCF↓, 2,   TumCG↓, 4,   Wnt↓, 4,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

AGRN↓, 1,   CD31↓, 1,   CDK4/6↓, 1,   COL2A1↓, 1,   COL9A3↓, 1,   E-cadherin↓, 2,   E-cadherin↑, 6,   fascin↓, 1,   Fibronectin↓, 2,   Galectin-9↓, 1,   GP1BB↓, 1,   ITGB4↓, 1,   ITGB6↓, 1,   LAMA5↓, 1,   miR-130a↓, 1,   miR-301a-3p↓, 1,   miR-320a↓, 1,   MMP2↓, 1,   MMP9↓, 2,   N-cadherin↓, 4,   Slug↓, 1,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   Snail↓, 2,   TET1↑, 1,   TGF-β↓, 1,   Trop2↓, 1,   TumCI↓, 6,   TumCMig↓, 9,   TumCP↓, 14,   TumMeta↓, 1,   Twist↓, 1,   Vim↓, 5,   Vim↑, 1,   α-SMA↓, 1,   β-catenin/ZEB1↓, 4,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   ATF4↑, 1,   ECM/TCF↓, 1,   EGFR↓, 2,   Hif1a↓, 1,   NO↑, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

MRP↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD25+↓, 1,   CD4+↓, 1,   COX2↓, 1,   FoxP3+↓, 1,   GM-CSF↓, 2,   HCAR1↓, 1,   IFN-γ↑, 1,   p‑IKKα↓, 1,   IL1↓, 1,   IL6↓, 1,   JAK↓, 1,   p‑JAK↓, 1,   p‑JAK2↓, 1,   p‑JAK3↓, 1,   MDSCs↓, 1,   MyD88↓, 1,   NF-kB↓, 2,   p65↓, 1,   p‑p65↓, 1,   PD-1↓, 1,   PD-L1↓, 1,   PD-L2↓, 1,   PGE2↓, 1,   T-Cell↑, 1,   TILs↑, 1,   TLR4↓, 2,  

Cellular Microenvironment ⓘ

pH↑, 1,   TIM-3↓, 1,  

Synaptic & Neurotransmission ⓘ

cholinesterase↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose∅, 2,   eff↓, 2,   eff↑, 1,   MDR1↓, 1,  

Clinical Biomarkers ⓘ

ALAT↑, 1,   Albumin↑, 1,   ALP↑, 1,   AST↑, 1,   EGFR↓, 2,   FOXM1↓, 2,   hTERT/TERT↓, 1,   IL6↓, 1,   Myc↓, 1,   PD-L1↓, 1,  

Functional Outcomes ⓘ

OS↑, 1,   TumVol↓, 4,   TumVol↑, 1,  

Infection & Microbiome ⓘ

Bacteria↑, 1,   CD8+↑, 1,  
Total Targets: 237

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 2,  

Migration ⓘ

miR-22↑, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,   TLR2↓, 1,  
Total Targets: 5

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:65  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page